Articles: erectile-dysfunction.
-
Controlled Clinical Trial
Effects of sildenafil on autonomic nervous function during sleep in obstructive sleep apnea.
To evaluate the effects of sildenafil on the autonomic nervous system in patients with severe obstructive sleep apnea. ⋯ The decrease in arousal response to apnea/hypopnea events along with the increase in HF(nu) components and decrease in LH/HF components of the heart rate variability ratio during slow wave sleep suggest that, in addition to worsening sleep apnea, sildenafil has potentially immediate cardiac effects in patients with severe obstructive sleep apnea.
-
Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND). ⋯ URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.
-
Int. J. Clin. Pract. · Mar 2010
ReviewCounterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.
Counterfeit drugs are inherently dangerous and a growing problem; counterfeiters are becoming increasingly sophisticated. Growth of the counterfeit medication market is attributable in part to phosphodiesterase type 5 inhibitor (PDE5i) medications for erectile dysfunction (ED). Millions of counterfeit PDE5is are seized yearly and account for the bulk of all counterfeit pharmaceutical product seizures. ⋯ Globally, increased obstacles for counterfeiters are necessary to combat pharmaceutical counterfeiting, including fines and penalties. The worldwide nature of the counterfeit problem requires proper coordination between countries to ensure adequate enforcement. Locally, physicians who treat ED need to inform patients of the dangers of ordering PDE5is via the Internet.
-
Studies have repeatedly confirmed that about 52% of men between the ages of 40 and 70 years have some degree of erectile dysfunction (ED). Other studies have shown that as a man ages, his testosterone level will naturally decrease. Over the last number of years, we have also seen that ED may be one of the earliest signs and markers of endothelial dysfunction. ⋯ It is very important for the primary care physician to identify patients who are suffering from ED and/or hypogonadism, and to also identify any other existing comorbidities. This article discusses the suggested work up, diagnosis, and management of men who present with either ED or symptoms and signs suggestive of hypogonadism (low testosterone). It also discusses the potential relationship between these conditions and metabolic syndrome.
-
Patient Prefer Adher · Nov 2009
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.
Erectile dysfunction (ED) is a problem that may affect up to 52% of men between the ages of 40 and 70. It can be distressing because of its negative effect on self-esteem, quality of life, and interpersonal relationships. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are now the first choice of treatment in ED. ⋯ Although the mechanism of action is the same for the three drugs, they differ in their pharmacokinetics. Several preference studies were conducted between the three PDE5 inhibitors but they were not free from bias. Because of the lack of overwhelming reliable data showing that one PDE5 inhibitor is superior to another, current opinion is that the individual patient should have the opportunity to test all three drugs and then select the one that best suits him and his partner.